Table 4: Predicted cardiovascular event rates,

life years, and discounted costs.

Outcomes

PHMD plus history of either MI or IS

HeFH

EVO+SoC

SoC

Difference

EVO+SoC

SoC

Difference

MACE*

1.35

1.71

-0.36

1.73

2.28

-0.55

MI

0.58

0.76

-0.18

0.82

1.14

-0.31

IS

0.14

0.18

-0.05

0.20

0.29

-0.09

CV death

0.63

0.77

-0.14

0.71

0.85

-0.15

Life years

 

 

 

 

 

 

Undiscounted

12.50

9.35

3.15

18.31

12.73

5.58

Discounted

8.28

6.69

1.59

10.71

8.42

2.29

Discounted costs ($)

1,180,405

625,845

554,560

1,415,406

731,747

683,660

LLT

564,395

8,772

555,623

738,120

18,893

719,227

Acute care

140,074

193,841

-53,767

149,003

228,601

-79,597

Follow-up

237,408

183,550

53,858

308,295

229,128

79,167

Revascularization

238,529

239,683

-1,154

219,988

255,125

-35,137

PHMD = primary hypercholesterolemia and mixed dyslipidemia;

HeFH = heterozygous familial hypercholesterolemia;

EVO = evolocumab;

SoC = standard of care;

MACE = major adverse cardiovascular event;

MI = myocardial infarction;

IS = ischemic stroke;

CV = cardiovascular;

LLT = lipid-lowering therapies.

* Expressed as per patient rate. Note: Costs are expressed in Mexican pesos.